Table 3.
Multivariate Cox regression analysis of irGGT elevation regarding overall survival
| PD-1 group (n = 217) |
Ipi + Nivo group (n = 146) |
|||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| irGGT elevation | ||||
| No | 1 | 1 | ||
| Yes | 0.37 (0.20–0.69) | 0.0016 | 0.33 (0.18–0.62) | 0.00050 |
| Liver metastasis | ||||
| No | 1 | 1 | ||
| Yes | 1.74 (1.17–2.57) | 0.0057 | 2.25 (1.28–3.94) | 0.0047 |
| LDH | ||||
| Normal | 1 | 1 | ||
| Elevated | 2.40 (1.64–3.50) | < 0.0001 | 1.48 (0.87–2.51) | 0.15 |
| Metastatic sites | ||||
| 1 | 1 | 1 | ||
| 2–4 | 1.08 (0.57–2.07) | 0.81 | 1.74 (0.76–4.01) | 0.19 |
| 5 or more | 1.80 (0.85–3.83) | 0.12 | 2.93 (1.19–7.18) | 0.019 |
| Prior therapies | ||||
| 0 | 1 | 1 | ||
| 1–2 | 1.40 (0.87–2.26) | 0.17 | 1.83 (1.03–3.25) | 0.040 |
| 3 or more | 1.78 (1.00–3.15) | 0.049 | 2.13 (0.95–4.77) | 0.066 |
Three cases of the PD-1 group and four cases of the Ipi + Nivo group were excluded due to missing information on one or more of the analyzed factors
CI confidence interval; GGT gamma-glutamyl transferase; HR hazard ratio; irGGT elevation, immune-related gamma-glutamyl transferase elevation; LDH lactate dehydrogenase; n number of patients; P p value